Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology
医学
人文学科
艺术
作者
Lorena Favaro Pavon,Tatiana Taís Sibov,Sílvia Regina Caminada de Toledo,Dutra de Oliveira,Francisco Romero Cabral,Jean Gabriel de Souza,Pamela Boufleur,Luciana Cavalheiro Marti,Jackeline Moraes Malheiros,Edgar Ferreira da Cruz,Fernando Fernandes Paiva,Suzana Mária Fleury Malheiros,Manoel Antônio de Paiva Neto,Alberto Tannús,Sônia Maria Junqueira Vasconcellos de Oliveira,Nasjla Saba Silva,Andréa Cappellano,Antônio Sérgio Petrilli,Ana Marisa Chudzinski‐Tavassi,Sérgio Cavalheiro
Background: Ependymoma (EPN), the third most common pediatric brain tumor, is a central nervous system (CNS) malignancy originating from the walls of the ventricular system.Surgical resection followed by radiation therapy has been the primary treatment for most pediatric intracranial EPNs.Despite numerous studies into the prognostic value of histological classification, the extent of surgical resection and adjuvant radiotherapy, there have been relatively few studies into the molecular and cellular biology of EPNs.Results: We elucidated the ultrastructure of the cultured EPN cells and characterized their profile of immunophenotypic pluripotency markers (CD133, CD90, SSEA-3, CXCR4).We established an experimental EPN model by the intracerebroventricular infusion of EPN cells labeled with multimodal iron oxide nanoparticles (MION), thereby generating a tumor and providing a clinically relevant animal model.MRI analysis was shown to be a valuable tool when combined with effective MION labeling techniques to accompany EPN growth.Conclusions: We demonstrated that GFAP/CD133+CD90+/CD44+ EPN cells maintained key histopathological and growth characteristics of the original patient tumor.The characterization of EPN cells and the experimental model could facilitate biological studies and preclinical drug screening for pediatric EPNs.www.oncotarget.com